Profile of NANOVIBRONIX INC(NASDAQ:NAOV) stock

NANOVIBRONIX INC0.3201

NASDAQ:NAOV (2/3/2023, 7:00:01 PM)-0.02 (-5.27%)

After market: 0.32 0 (-0.03%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS Sector	Health Care
GICS Industry	Health Care Equipment & Supplies

Chartmill FA Rating

Valuation		Growth
Profitability		Health
Dividend

Overview

Earnings (Last)	11-14 2022-11-14/bmo	Earnings (Next)	N/A N/A
Ins Owners	0.4%	Inst Owners	4.5%
Market Cap	10.50M	Shares	32.79M
PE	N/A	Fwd PE	N/A
Dividend Yield	N/A	Analysts	82.86
IPO	04-24 2015-04-24

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The company is headquartered in Elmsford, New York and currently employs 12 full-time employees. The company went IPO on 2015-04-24. The firm is focused on developing noninvasive biological response-activating devices utilizing its low intensity surface acoustic wave (SAW) technology, which targets biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products, which are in various stages of clinical and market development consist of UroShield, PainShield and WoundShield. Its UroShield is an ultrasound-based product that prevents bacterial colonization and biofilm in urinary catheters. Its PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures. Its PainShield family of products include PainShield MD, PainShield Plus and PainShield Relief. WoundShield is a patch-based therapeutic ultrasound device developed to facilitate tissue regeneration and wound healing. Its wholly owned subsidiary is NanoVibronix Ltd.